Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record
Rhea-AI Summary
Aspire Biopharma (NASDAQ:ASBP) announced on February 19, 2026 that its subsidiary BUZZ BOMB™ Caffeine Company named ChicExecs as its public relations agency of record as it pursues brand expansion, product innovation, and a comprehensive brand refresh.
ChicExecs will lead media relations, events, strategic partnerships, and PR campaigns to position BUZZ BOMB™—a 50mg sublingual caffeine powder in single-serving stick packs—across food, beverage, fitness, and lifestyle channels.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Sector peers showed mixed but generally soft action, with ICU and QTTB in momentum scans moving down while FBLG moved up. This indicates broader biotech volatility alongside this company-specific PR news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Patent filing meclizine | Positive | +11.2% | Provisional patent for fast-acting sublingual meclizine formulation. |
| Feb 13 | Board appointment | Positive | +9.2% | Appointment of experienced capital markets executive to Board and committees. |
| Feb 12 | Patent filing ondansetron | Positive | -3.0% | Provisional patent for rapid-onset sublingual ondansetron formulation. |
| Feb 11 | Private placement | Positive | -4.3% | Up to $21M Series A convertible preferred financing to strengthen balance sheet. |
| Feb 10 | Nasdaq compliance | Positive | -2.1% | Regained compliance with Nasdaq minimum bid price requirement. |
Positive IP and governance news has often seen supportive or mixed price reactions, while capital-raising and compliance items have more frequently coincided with pressure.
In the past weeks, Aspire Biopharma reported several strategic steps: regaining Nasdaq minimum bid compliance on Feb 10, 2026, a $21.0 million private placement announcement on Feb 11, and provisional patents for sublingual ondansetron and meclizine on Feb 12 and Feb 17. A board refresh was disclosed on Feb 13. Patent and governance news drew positive reactions, while financing and compliance items often coincided with downward moves. Today’s PR-focused Buzz Bomb announcement fits into a broader repositioning and commercialization narrative.
Market Pulse Summary
This announcement highlights Aspire’s push to expand BUZZ BOMB™, a sublingual caffeine stick-pack delivering 50 mg of caffeine in four flavors, by engaging ChicExecs, an agency with offices in six states and over 250 brands. In context, the company recently pursued patent filings, a $21.0 million private placement, and Nasdaq compliance steps. Investors may watch how this PR-driven strategy translates into revenue growth, supports its broader sublingual platform, and interacts with ongoing financing and governance initiatives.
Key Terms
sublingual delivery medical
AI-generated analysis. Not financial advice.
ESTERO, FL / ACCESS Newswire / February 19, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company") today announced that its wholly owned subsidiary Buzz Bomb Caffeine Company - marketer of a proprietary caffeine supplement - has named ChicExecs as its public relations agency of record.
The appointment comes as BUZZ BOMB™ gears up for a transformative year focused on aggressive brand expansion, product innovation, and a refreshed market presence. ChicExecs, a powerhouse agency with offices in six states and a portfolio of over 250 global brands, will spearhead BUZZ BOMB™'s communications strategy. The focus includes media relations, high-impact events, strategic partnerships, and PR-led campaign planning.
"The ChicExecs team is thrilled to partner with Buzz Bomb Caffeine as they reshape the energy category, delivering sharp focus, instant energy, and no crash," said Kristen Wessel, Senior Vice President of Public Relations at ChicExecs. "Their innovative approach to clean, convenient energy solutions aligns seamlessly with our mission to elevate trailblazing brands. We're excited to amplify their journey, grow their audience, and drive meaningful growth in the marketplace through this exciting new partnership."
"As BUZZ BOMB™ enters this next stage of growth, we are thrilled to partner with ChicExecs to bring our brand story to life in new and meaningful ways," said Kraig Higginson, Interim CEO of Aspire. "Together, we are redefining how we connect with consumers, highlighting our innovative formulation, and reinforcing our leadership in the rapid caffeine delivery space. ChicExecs' decades of experience in elevating mission-driven brands makes them the ideal collaborator to amplify our reach."
The partnership marks a pivotal chapter for BUZZ BOMB™ as it leverages a comprehensive brand refresh. ChicExecs will utilize its deep sector expertise in food and beverage, fitness, and lifestyle products to position BUZZ BOMB™ as the premier innovator for athletes, professionals, and anyone requiring a rapid, efficient energy boost. Beyond consumer awareness, the agency will also drive thought-leadership campaigns to support Aspire's broader corporate recruitment and industry positioning.
BUZZ BOMB™ Caffeine and Sublingual Delivery
Unlike traditional energy drinks or pills, BUZZ BOMB™ utilizes a proprietary format delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method provides flavored caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee or soda.
BUZZ BOMB™ features 50mg of caffeine and is currently offered in four flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise serving of caffeine in easy-to-use single-serving stick packs.
To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com.
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma delivers supplements to the body rapidly and precisely.
For more information, please visit www.aspirebiolabs.com.
Aspire Biopharma Holdings, Inc.
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Aspire Biopharma (ASBP) announce on February 19, 2026 about BUZZ BOMB™?
How will the ChicExecs appointment affect BUZZ BOMB™ marketing and reach for ASBP?
What is BUZZ BOMB™'s product format and caffeine content (ASBP product details)?
Will the ChicExecs partnership support Aspire Biopharma's corporate positioning and hiring?
Where can consumers purchase BUZZ BOMB™ products promoted by ASBP and ChicExecs?
